Drug Trial Radar · NCT02409667
Plaque Psoriasis Efficacy and Safety With Secukinumab
Last checked: Nov 20, 2026Latest source record: May 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16,487
Actual
Start
May 7, 2015
Primary completion
Mar 14, 2017
Study completion May 8, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.
Conditions
- Plaque Psoriasis
Interventions
SecukinumabBiological
Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24Time frame: Week 52
Locations
200 sites in 24 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Innsbruck, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Loverval, Belgium
Novartis Investigative Site
Jette, Brussels Capital, Belgium
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Stara Zagora, Bulgaria
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Sofia, BGR, Bulgaria
Novartis Investigative Site
Ivanić-Grad, Croatia
Novartis Investigative Site
Osijek, Croatia
Novartis Investigative Site
Zagreb, Croatia
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Brno, Czech Republic, Czechia
Novartis Investigative Site
Ostrava Poruba, Czech Republic, Czechia
Novartis Investigative Site
Prague, Czech Republic, Czechia
Novartis Investigative Site
Arhus C, Denmark
Novartis Investigative Site
Hellerup, Denmark
Novartis Investigative Site
Tampere, Finland
Novartis Investigative Site
Turku, Finland
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Grenoble, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Rouen, France
Novartis Investigative Site
Saint-Etienne, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Trévenans, France
Showing 40 of 200 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.